The present invention relates to an immune cell with higher cytotoxic activity, and a pharmaceutical composition for NK cell therapy which can be expected to have a higher effect. The present invention provides a cell population comprising cells that are CCR5 positive, CCR6 positive, and CXCR3 positive and CD3 negative. The present invention provides a group of cells that are CCR5 positive, CCR6 positive, and CXCR3 positive and CD3 negative, and further CD11c highly expressive. The present invention provides a CCR5-positive, CCR6-positive, and CXCR3-positive CD3-negative cell that infiltrates into a solid tumor. The present invention also provides a pharmaceutical composition comprising such a cell group and an additive permitted as a medicine. Furthermore, this invention provides the manufacturing method of the said cell group.本發明係關於一種細胞毒殺活性更高之免疫細胞、及可期待較高效果之用於NK細胞療法之醫藥組合物。本發明提供一種包含為CCR5陽性、CCR6陽性及CXCR3陽性且為CD3陰性之細胞之細胞集團。本發明提供一種為CCR5陽性、CCR6陽性及CXCR3陽性且為CD3陰性之細胞進而為CD11c高表現性之細胞集團。本發明提供一種浸潤至固體腫瘤之為CCR5陽性、CCR6陽性及CXCR3陽性且為CD3陰性之細胞。又，本發明提供一種包含此種細胞集團及作為醫藥而容許之添加物之醫藥組合物。進而，本發明提供一種上述細胞集團之製造方法。
